Ultrasound Guided Interscalene, Suprascapular and Anterior Glenoid Nerve Blocks on Diaphragmatic Excursion and Analgesia Following Arthroscopic Shoulder Surgery

NCT07090733 | Recruiting

• 1 other identifier: 36265MD/12/24
• Study Type: interventional
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

This study aims to evaluate the diaphragmatic movement and postoperative analgesia following anterior glenoid, suprascapular, and interscalene nerve blocks in patients undergoing elective arthroscopic shoulder surgery.

Conditions

Interscalene Block; Suprascapular Nerve Block; Anterior Glenoid Nerve Block; Diaphragmatic Excursion; Analgesia; Arthroscopic Shoulder Surgery

Outcome Measures

Primary Outcomes (1)

• Incidence of hemi-diaphragmatic paralysis

  Incidence of hemi-diaphragmatic paralysis determined by ultrasound-guided assessment of diaphragmatic excursion. Diaphragmatic excursion will be measured before procedure (pre-block), 30 minutes after performing the block and post operative after complete recovery in post-anesthesia care unit (PACU).

  24 hours postoperatively

Secondary Outcomes (3)

• Degree of pain

  24 hours postoperatively

• Total analgesic consumption

  24 hours postoperatively

• Degree of patient satisfaction

  24 hours postoperatively

Study Arms (4)

Group I

ACTIVE COMPARATOR

Patients will receive general anesthesia, plus an ultrasound-guided Interscalene brachial plexus block (ISB) with the injection of 15 mL of 0.25% bupivacaine. Patients will receive general anesthesia plus an ultrasound-guided suprascapular nerve block (SSNB)

Other: Interscalene brachial plexus block

Group II

EXPERIMENTAL

Patients will receive general anesthesia plus an ultrasound-guided suprascapular nerve block (SSNB) with injection of 15 ml of 0.25% bupivacaine.

Other: Suprascapular nerve block

Group III

EXPERIMENTAL

Patients will receive general anesthesia plus an ultrasound-guided anterior glenoid block with injection of 15 ml of 0.25% bupivacaine.

Other: Anterior glenoid block

Group IV

EXPERIMENTAL

Patients will receive general anesthesia, along with a total volume of 30 mL of bupivacaine 0.25%, divided into 15 mL of Bupivacaine 0.25% for ultrasound-guided SSNB and 15 mL of Bupivacaine 0.25% for ultrasound-guided anterior glenoid block.

Other: Suprascapular nerve block + Anterior glenoid block

Interventions

Interscalene brachial plexus block OTHER

Patients will receive general anesthesia, plus an ultrasound-guided interscalene brachial plexus block (ISB) with the injection of 15 mL of 0.25% bupivacaine.

Also known as: 15 ml of 0.25% bupivacaine

Group I

Suprascapular nerve block OTHER

Patients will receive general anesthesia plus an ultrasound-guided suprascapular nerve block (SSNB) with injection of 15 ml of 0.25% bupivacaine.

Also known as: 15 ml of 0.25% bupivacaine

Group II

Anterior glenoid block OTHER

Patients will receive general anesthesia plus an ultrasound-guided anterior glenoid block with injection of 15 ml of 0.25% bupivacaine.

Also known as: 15 ml of 0.25% bupivacaine

Group III

Suprascapular nerve block + Anterior glenoid block OTHER

Patients will receive general anesthesia, along with a total volume of 30 mL of 0.25% bupivacaine, divided into 15 mL for ultrasound-guided SSNB and 15 mL for ultrasound-guided anterior glenoid block.

Also known as: 30 mL of 0.25% bupivacaine

Group IV

Eligibility Criteria

• Age: 21 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age from 21 to 65 years.
• Both sexes.
• American Society of Anesthesiologists (ASA) physical status I or II.
• Scheduled for arthroscopic shoulder surgery.

You may not qualify if:

• Patient's refusal to participate.
• Patients with a history of allergy to local anesthetics.
• Patients with a history of chronic use of painkillers.
• Patients presented with mental dysfunction.
• Patients with coagulation disorders.
• Patients presented with skin or soft tissue infection at the proposed site of needle Insertion.
• Pregnant Patients.
• Patients with Chronic Obstructive Pulmonary Disease (COPD) or a Body Mass Index (BMI) of more than 40.

Sponsors & Collaborators

• Tanta University: lead

Study Sites (1)

Tanta University

Tanta, El-Gharbia, 31527, Egypt

RECRUITING

MeSH Terms

Conditions

Agnosia

Interventions

Bupivacaine

Condition Hierarchy (Ancestors)

Perceptual Disorders; Neurobehavioral Manifestations; Neurologic Manifestations; Nervous System Diseases; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Anilides; Amides; Organic Chemicals; Aniline Compounds; Amines

Central Study Contacts

Fatma E Elsamahy, Master

CONTACT

00201094082899; Drfatmaelsamahy@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt

Study Record Dates

• First Submitted: July 21, 2025
• First Posted: July 29, 2025
• Study Start: January 1, 2025
• Primary Completion: December 31, 2025
• Study Completion: December 31, 2025
• Last Updated: July 29, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL
• Time Frame: After the end of study for one year.
• Access Criteria: The data will be available upon a reasonable request from the corresponding author.

Locations

EG (1)